image dons

I make a donation

REMINDER

Evaluate the effect of eplerenone on cardiovascular mortality and morbidity in patients having a myocardial infarct under treatment

Terminée

Remerciements de la Famille COLLET

Prix de Recherche Pr Jean-Philippe COLLET

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

logo étude

objectif

Impact of eplerenone on cardiovascular outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset.

date de réalisation

2010

nombre de patients

1013

nombre de centres participants

68 centers in 11 countries

type de financement

Private (Pfizer)

Référence

NCT01176968

A Double-blind, Randomized, Placebo-controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction (REMINDER)

Study Description

We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset.

source clinicaltrials.gov

Publication

  • Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure : the Randomized Double-Blind Reminder Study
    Gilles Montalescot, Bertram Pitt, Esteban Lopez de Sa, Christian W Hamm, Marcus Flather, Freek Verheugt, Harry Shi, Eva Turgonyi, Miguel Orri, John Vincent, Faiez Zannad, REMINDER Investigators
    Publicated in European Heart Journal

Presentation

Autres études

+

BIO-TAVI

En cours

Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI
Lire la suite
+

AMUNDSEN

En cours

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....
Lire la suite
+

ARAMIS

En cours

Evaluation of Anakinra versus placebo in treatment of acute myocarditis and evaluation of the contuity of the reference treatment with IEC in patients without ventricular dysfunction ventriculaire.
Lire la suite